We use cookies to help provide you with the best possible online experience. Please read our Privacy Policy for information about which cookies we use and what information we collect on our site. By continuing to use this site, you agree that we may store and access cookies on your device.

I Agree

You are here: Industry Insights > PAH

News List

PAH patients in England denied access to Actelion’s Uptravi on NHS pharmatimes
July 10, 2018
Actelion’s Uptravi will not be funded on the NHS for patients with Pulmonary Arterial Hypertension (PAH), after the drug failed to make it into NHS England’s latest round of specialised commissioning approvals.
Liquidia files for IPO to challenge United Therapeutics in PAH fiercebiotech
July 09, 2018
Liquidia Technologies has filed for a $57.5 million IPO to take its twist on United Therapeutics’ Tyvaso through phase 3.
EU safety review backs continued use Uptravi for PAH pharmatimes
April 12, 2017
European regulators have ruled that Actelion’s Uptravi can continue to be used as per its prescribing information to treat...

Previous page 1 2 Next page